Effect of botulinum toxin type A on muscular temporomandibular disorder: A systematic review and meta‐analysis of randomized controlled trials
Journal of Oral Rehabilitation · 2024-05 · 51 (5) · 886-897
DOI: 10.1111/joor.13648 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Journal of Oral Rehabilitation, online erschienen am 27.12.2023. Verfasst von Kaiyang Li und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Faculty of Medicine and Health Sciences, McGill University, Montreal, Quebec, Canada. Hauptthemen laut MEDLINE: Botulinum Toxins, Type A, Randomized Controlled Trials as Topic, Temporomandibular Joint Disorders, Neuromuscular Agents. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Botulinum toxin type A (BTX‐A) is increasingly used to manage painful temporomandibular disorders (TMD). However, the effect of BTX‐A on muscular TMD remains unclear.
Objective
To assess the efficacy, safety and optimal dose of BTX‐A for treating TMD.
Methods
We conducted systematic literature searches in MEDLINE, Embase, Web of Science, ClinicalTrials.gov and Cochrane Library until March 2023. We extracted data from randomized controlled trials (RCTs) that evaluated the efficacy and safety of BTX‐A in treating muscular TMD. We performed a meta‐analysis using a random‐effects model.
Results
Fifteen RCTs involving 504 participants met the inclusion criteria. BTX‐A was significantly more effective than placebo in reducing pain intensity, as measured on a 0–10 scale, at 1 month (MD [95% CI] = −1.92 [−2.87, −0.98], p < .0001) and 6 months (MD [95% CI] −2.08, [−3.19 to −0.98]; p = .0002). A higher dosage of BTX‐A (60–100 U bilaterally) was associated with a greater reduction in pain at 6 months (MD [95% CI] = −2.98 [−3.52, −2.44]; p < .001). BTX‐A also resulted in decreased masseter muscle intensity (μV) (MD [95% CI] = −44.43 [−71.33, −17.53]; p = .001) at 1 month and occlusal force (kg) at 3 months (MD [95% CI] = −30.29 [−48.22 to −12.37]; p = .0009). There was no significant difference in adverse events between BTX‐A and placebo.
Conclusions
BTX‐A is a safe and effective treatment for reducing pain and improving temporomandibular muscle and joint function in muscular TMD patients. A bilateral dose of 60–100 U might be an optimal choice for treating muscular TMD pain.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Faculty of Medicine and Health Sciences, McGill University, Montreal, Quebec, Canada.
- Schulich School of Medicine & Dentistry, Western University, London, Ontario, Canada.
ORCID-Profile: Kaiyang Li, Wei Guang Bi
Zitieren
APA
Li, K., Tan, K., Yacovelli, A., & Bi, W. G. (2024). Effect of botulinum toxin type A on muscular temporomandibular disorder: A systematic review and meta‐analysis of randomized controlled trials. Journal of Oral Rehabilitation, 51(5), 886-897. https://doi.org/10.1111/joor.13648
Vancouver
Li K, Tan K, Yacovelli A, Bi WG. Effect of botulinum toxin type A on muscular temporomandibular disorder: A systematic review and meta‐analysis of randomized controlled trials. Journal of Oral Rehabilitation. 2024;51(5):886-897. doi:10.1111/joor.13648
BibTeX
@article{Li2024,
author = {Li, Kaiyang and Tan, Kenneth and Yacovelli, Alexandra and Bi, Wei Guang},
title = {Effect of botulinum toxin type A on muscular temporomandibular disorder: A systematic review and meta‐analysis of randomized controlled trials},
journal = {Journal of Oral Rehabilitation},
year = {2024},
volume = {51},
number = {5},
pages = {886--897},
doi = {10.1111/joor.13648}
}
EUVIMED